The impact of postoperative complications following cytoreductive surgery combined with oxaliplatin based heated intraperitoneal chemotherapy.

[1]  R. Carleer,et al.  Body surface area‐based vs concentration‐based perioperative intraperitoneal chemotherapy after optimal cytoreductive surgery in colorectal peritoneal surface malignancy treatment: COBOX trial , 2019, Journal of surgical oncology.

[2]  K. Turaga,et al.  Cytoreduction and hyperthermic intraperitoneal chemotherapy in metastatic colorectal cancer , 2019, Journal of surgical oncology.

[3]  B. Rau,et al.  Morbidity and Mortality Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Data from the DGAV StuDoQ Registry with 2149 Consecutive Patients , 2018, Annals of Surgical Oncology.

[4]  R. Pai,et al.  Postoperative Complications Independently Predict Cancer-Related Survival in Peritoneal Malignancies , 2018, Annals of Surgical Oncology.

[5]  K. Soo,et al.  Platinum agents and mitomycin C-specific complications in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) , 2018, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[6]  L. Battaglia,et al.  Learning Curve, Training Program, and Monitorization of Surgical Performance of Peritoneal Surface Malignancies Centers. , 2018, Surgical oncology clinics of North America.

[7]  M. Schneider,et al.  Major Postoperative Complications Are a Risk Factor for Impaired Survival after CRS/HIPEC , 2017, Annals of Surgical Oncology.

[8]  V. Lemmens,et al.  Short-term outcome in patients treated with cytoreduction and HIPEC compared to conventional colon cancer surgery , 2016, Medicine.

[9]  E. Cotte,et al.  Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin Increases the Risk of Postoperative Hemorrhagic Complications: Analysis of Predictive Factors , 2016, Annals of surgical oncology.

[10]  Deepesh Agarwal,et al.  Complications of Cytoreductive Surgery and HIPEC in the Treatment of Peritoneal Metastases , 2016, Indian Journal of Surgical Oncology.

[11]  K. Turaga,et al.  Impact of surgical volume of centers on post-operative outcomes from cytoreductive surgery and hyperthermic intra-peritoneal chemoperfusion. , 2016, Journal of gastrointestinal oncology.

[12]  Andrew D. Newton,et al.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a review of factors contributing to morbidity and mortality. , 2016, Journal of gastrointestinal oncology.

[13]  K. Havenga,et al.  Cytoreduction and hyperthermic intraperitoneal chemotherapy: The learning curve reassessed. , 2016, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[14]  G. Salti,et al.  Evaluation of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a community setting: A cost‐utility analysis of a hospital's initial experience and reflections on the health care system , 2016, Journal of surgical oncology.

[15]  D. Morris,et al.  Clinical features of pulmonary emboli in patients following cytoreductive surgery (peritonectomy) and hyperthermic intraperitoneal chemotherapy (hipec), a single centre experience. , 2015, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[16]  J. Spiliotis,et al.  Cytoreductive surgery and HIPEC for peritoneal carcinomatosis. A review on morbidity and mortality. , 2015, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[17]  G. Nieuwenhuijzen,et al.  Serious Postoperative Complications Affect Early Recurrence After Cytoreductive Surgery and HIPEC for Colorectal Peritoneal Carcinomatosis , 2015, Annals of Surgical Oncology.

[18]  J. Pelz,et al.  American Society of peritoneal surface malignancies opinion statement on defining expectations from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer , 2014, Journal of surgical oncology.

[19]  S. Bonomi,et al.  Postoperative Complications After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Affect Long-term Outcome of Patients With Peritoneal Metastases From Colorectal Cancer: a Two-Center Study of 101 Patients , 2014, Diseases of the colon and rectum.

[20]  S. Bruin,et al.  The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: A comparative study , 2014, Journal of surgical oncology.

[21]  K. Havenga,et al.  Cytoreduction and HIPEC in The Netherlands: Nationwide Long-term Outcome Following the Dutch Protocol , 2013, Annals of Surgical Oncology.

[22]  S. Laurberg,et al.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: the Danish experience , 2013, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[23]  P. Pattyn,et al.  Effect of perfusion temperature on glucose and electrolyte transport during hyperthermic intraperitoneal chemoperfusion (HIPEC) with oxaliplatin. , 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[24]  H. Schlitt,et al.  Treatment‐related morbidity and toxicity of CRS and oxaliplatin‐based HIPEC compared to a mitomycin and doxorubicin‐based HIPEC protocol in patients with peritoneal carcinomatosis: A matched‐pair analysis , 2013, Journal of surgical oncology.

[25]  T. Chua,et al.  Evaluation of the Cost-Effectiveness of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (Peritonectomy) at the St George Hospital Peritoneal Surface Malignancy Program , 2010, Annals of surgery.

[26]  M. Kirstein,et al.  Severe Electrolyte Disturbances After Hyperthermic Intraperitoneal Chemotherapy: Oxaliplatin Versus Mitomycin C , 2010, Annals of Surgical Oncology.

[27]  F. Zoetmulder,et al.  Learning curve of combined modality treatment in peritoneal surface disease , 2007, The British journal of surgery.

[28]  F. Zoetmulder,et al.  Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei--a report of 103 procedures. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[29]  Hung-Ming Wang,et al.  Phase I dose escalation study of oxaliplatin combined with oral tegafur–uracil and leucovorin in patients with advanced gastric cancer , 2005, Anti-cancer drugs.

[30]  H. Tinteren,et al.  Toxicity of cytoreductive surgery and hyperthermic intra‐peritoneal chemotherapy , 2004, Journal of surgical oncology.